Peter J. O'Dwyer

Increased DT-diaphorase expression and cross-resistance to mitomycin C in a series of cisplatin-resistant human ovarian cancer cell lines.

A. Godwin, R. Perez, P. O'dwyer, 1996, Biochemical pharmacology.

Phase I clinical/pharmacokinetic and pharmacodynamic trial of the c-raf-1 antisense oligonucleotide ISIS 5132 (CGP 69846A).

P. O'dwyer, K. Yao, B. Monia, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Glutathione and drug resistance.

R. Ozols, A. Godwin, K. Tew, 1996, Cancer investigation.

Activation of AP-1 and of a nuclear redox factor, Ref-1, in the response of HT29 colon cancer cells to hypoxia.

T. Curran, P. O'dwyer, K. Yao, 1994, Molecular and cellular biology.

Evidence for altered regulation of gamma-glutamylcysteine synthetase gene expression among cisplatin-sensitive and cisplatin-resistant human ovarian cancer cell lines.

R. Ozols, A. Godwin, P. O'dwyer, 1995, Cancer research.

A phase I safety and pharmacokinetic (PK) study of recombinant Apo2L/TRAIL, an apoptosis-inducing protein in patients with advanced cancer.

R. Herbst, R. Kurzrock, W. Novotny, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical studies of reversal of drug resistance based on glutathione.

P. O'dwyer, K. Yao, T. Hamilton, 1998, Chemico-biological interactions.

Activation of AP-1 and of a nuclear redox factor, Ref-1, in the response of HT29 colon cancer cells to hypoxia

T. Curran, P. O'dwyer, K. Yao, 1994 .

Modulation of glutathione and related enzymes in reversal of resistance to anticancer drugs.

R. Ozols, K. Tew, P. O'dwyer, 1995, Hematology/oncology clinics of North America.